论文部分内容阅读
近年来,细胞免疫的体外测定技术发展极为迅速,但往往由于测定方法的烦琐、耗血量大、设备较多、费时等因素而限制了它们在临床的应用和推广,因而迫切需要方法简便、敏感、能重复而特异的肿瘤细胞免疫测定技术来研究肿瘤的早期诊断、治疗效果及预后判断。1972年Halliday等在白细胞移动抑制试验基础上发展起来的白细胞粘附抑制(Leukocyte Adherence Inhibition Test简称LAI)试验,由于初步具备上述条件而受
In recent years, in vitro assays for cellular immunity have developed rapidly. However, due to cumbersome assays, large amounts of blood, large amounts of equipment, and time-consuming factors, they have limited their clinical application and promotion. Therefore, there is an urgent need for methods that are simple, Sensitive, reproducible and specific tumor cell immunoassay techniques are used to study the early diagnosis, treatment effect and prognosis of tumors. The Leukocyte Adherence Inhibition (LAI) test developed by Halliday et al. on the basis of the leukocyte migration inhibition test in 1972 was initially subjected to the above-mentioned conditions.